Endoscopic therapy of Barrett’s: what more do we need to know?

Por Van Laethem, J-L, Devière, J
Publicado em 2004

Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results

Por Van Laethem, J-L, Cremer, M, Peny, M, Delhaye, M, Deviere, J
Publicado em 1998

Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus

Por Van Laethem, J L, Peny, M, Salmon, I, Cremer, M, Deviere, J
Publicado em 2000

Adenocarcinoma arising in columnar lined oesophagus following treatment with argon plasma coagulation

Por SHAND, A, DALLAL, H, PALMER, K, GHOSH, S, MACINTYRE, M, VAN LAETHEM, J-L
Publicado em 2001

Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice

Por Van Laethem, J-L, Eskinazi, R, Louis, H, Rickaert, F, Robberecht, P, Deviere, J
Publicado em 1998

Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours.

Por Van Laethem, J L, Vertongen, P, Deviere, J, Van Rampelbergh, J, Rickaert, F, Cremer, M, Robberecht, P
Publicado em 1995

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

Por Demols, A, Peeters, M, Polus, M, Marechal, R, Gay, F, Monsaert, E, Hendlisz, A, Van Laethem, J L
Publicado em 2006

DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

Por Drouillard, A, Puleo, F, Bachet, J B, Ouazzani, S, Calomme, A, Demetter, P, Verset, G, Van Laethem, J L, Maréchal, R
Publicado no Br J Cancer (2016)

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma

Por Maréchal, R, Demetter, P, Nagy, N, Berton, A, Decaestecker, C, Polus, M, Closset, J, Devière, J, Salmon, I, Van Laethem, J-L
Publicado em 2009

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma

Por Maréchal, R, Demetter, P, Nagy, N, Berton, A, Decaestecker, C, Polus, M, Closset, J, Devière, J, Salmon, I, Van Laethem, J-L
Publicado em 2010

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study

Por Verset, G, Verslype, C, Reynaert, H, Borbath, I, Langlet, P, Vandebroek, A, Peeters, M, Houbiers, G, Francque, S, Arvanitakis, M, Van Laethem, J-L
Publicado em 2007

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

Por Van Cutsem, E, Dirix, L, Van Laethem, J-L, Van Belle, S, Borner, M, Gonzalez Baron, M, Roth, A, Morant, R, Joosens, E, Gruia, G, Sibaud, D, Bleiberg, H
Publicado em 2005

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic a...

Por Ramanathan, R. K., Goldstein, D., Korn, R. L., Arena, F., Moore, M., Siena, S., Teixeira, L., Tabernero, J., Van Laethem, J.-L., Liu, H., McGovern, D., Lu, B., Von Hoff, D. D.
Publicado no Ann Oncol (2016)

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

Por Van Cutsem, E, Li, C-P, Nowara, E, Aprile, G, Moore, M, Federowicz, I, Van Laethem, J-L, Hsu, C, Tham, C K, Stemmer, S M, Lipp, R, Zeaiter, A, Fittipaldo, A, Csutor, Z, Klughammer, B, Meng, X, Ciuleanu, T
Publicado no Br J Cancer (2014)

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the panc...

Por Fuchs, C. S., Azevedo, S., Okusaka, T., Van Laethem, J.-L., Lipton, L. R., Riess, H., Szczylik, C., Moore, M. J., Peeters, M., Bodoky, G., Ikeda, M., Melichar, B., Nemecek, R., Ohkawa, S., Świeboda-Sadlej, A., Tjulandin, S. A., Van Cutsem, E., Loberg, R., Haddad, V., Gansert, J. L., Bach, B. A., Carrato, A.
Publicado no Ann Oncol (2015)